The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.
On Jan. 15, 2025, a warning letter was sent to Sanofi stating that FDA inspectors found irregularities with the facility's bioreactor, the vessel used to grow organisms and cells. According to the ...
As you can see from the chart above the percentage of shares that are sold short for Sanofi has grown since its last report. This does not mean that the stock is going to fall in the near-term but ...
Ellison accused Novo Nordisk, Eli Lilly and Sanofi of inflating patients' out-of-pocket costs for insulin based on the wholesale acquisition cost, or list price, of the drug. The drugmakers were ...
As part of its enforcement activities, the Food and Drug Administration (FDA) sends warning letters to entities under its jurisdiction. Some letters are not posted for public view until weeks or ...
Federal regulators have warned a Waco company that its human amniotic products are “unlicensed” and “unapproved,” and that ...
The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback